Abstract
TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Dixit VM . 1998 Science 281: 1305–1308
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . 1999 J. Clin. Invest. 104: 155–162
Baeuerle PA, Baltimore D . 1996 Cell 87: 13–20
Beauparlant P, Kwan I, Bitaar R, Chou P, Koromilas AE, Sonenberg N, Hiscott J . 1994 Oncogene 9: 3189–3197
Beg AA, Baltimore D . 1996 Science 274: 782–784
Blay J-Y, Rossi J-F, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M . 1997 Int. J. Cancer 72: 424–430
Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L . 1997 Immunity 7: 821–830
Frank S, Kohler U, Schackert G, Schackert HK . 1999 Biochem. Biophys. Res. Commun. 257: 454–459
Gilmore TD, Koedood M, Piffat KA, White D . 1996 Oncogene 13: 1367–1378
Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . 1998 Blood 91: 4624–4631
Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S . 1999 Cancer Res. 59: 734–741
Kim K, Fisher MJ, Xu S-Q, El-Deiry WS . 2000 Clin. Cancer Res. 6: 335–346
Kothny-Wilkes G, Kulms D, Pöppelmann B, Luger TA, Kubin M, Schwarz T . 1998 J. Biol. Chem. 273: 29247–29253
Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldegrun A . 1997 Cancer Res. 57: 5189–5195
Pan G, Ni J, Wei Y-J, Yu G-L, Gentz R, Dixit VM . 1997 Science 277: 815–818
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . 1996 J. Biol. Chem. 271: 12687–12690
Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . 1998 FEBS Letts. 427: 124–128
Ritchie AWS, Chisholm GD . 1983 Semin. Oncol. 10: 390–400
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramarkrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A . 1997 Science 277: 818–821
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenschein GE . 1997 J. Clin. Invest. 100: 2952–2960
Sumitomo M, Tachibana T, Ozu C, Asakura A, Murai M, Hayakawa M, Nakamura H, Takayanagi A, Shimizu N . 1999 Hum. Gene Ther. 9: 37–47
Tachibana M, Miyakawa A, Nakashima J, Murai M, Nakamura K, Kubo A, Hata J . 2000 Cell Tissue Res. 301: 353–367
Thornberry NA, Lazebnik Y . 1998 Science 281: 1312–1316
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S . 1995 Genes Dev. 9: 2723–2735
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Shuh JC, Lynch DH . 1999 Nat. Med. 5: 157–163
Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . 1998 Science 281: 1680–1683
Wang W, Abbruzzese JL, Evans DB, Larry L, Clleary KR, Chao PJ . 1999 Clin. Cancer Res. 5: 119–127
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA . 1995 Immunity 3: 673–682
Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P . 1999 Cancer Res. 59: 2747–2753
Acknowledgements
This study was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oya, M., Ohtsubo, M., Takayanagi, A. et al. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20, 3888–3896 (2001). https://doi.org/10.1038/sj.onc.1204525
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204525
Keywords
This article is cited by
-
Modeling the therapeutic efficacy of NFκB synthetic decoy oligodeoxynucleotides (ODNs)
BMC Systems Biology (2018)
-
Developing TRAIL/TRAIL death receptor-based cancer therapies
Cancer and Metastasis Reviews (2018)
-
Identification of genes and pathways involved in kidney renal clear cell carcinoma
BMC Bioinformatics (2014)
-
NF-κB and cancer: how intimate is this relationship
Molecular and Cellular Biochemistry (2010)
-
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
British Journal of Cancer (2009)